Combination of mitomycin, vindesine, and cisplatin in the treatment of head and neck squamous cell carcinoma

Details

Serval ID
serval:BIB_F431806F8FF6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Combination of mitomycin, vindesine, and cisplatin in the treatment of head and neck squamous cell carcinoma
Journal
Cancer Treatment Reports
Author(s)
Leyvraz  S., Barrelet  L., Savary  M., Bernasconi  S.
ISSN
0027-8874
0361-5960 (Print)
Publication state
Published
Issued date
01/1987
Volume
71
Number
1
Pages
81-2
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jan
Abstract
Thirty patients with squamous cell carcinoma of the head and neck were treated with a combination of mitomycin (10 mg/m2, Day 1), vindesine (3 mg/m2, Days 1 and 8), and cisplatin (60 mg/m2, Day 1), repeated every 28 days. Seven patients were previously treated by surgery, radiotherapy, or chemotherapy, and 23 had untreated advanced tumors. Objective responses were seen in 17 of 27 evaluable patients (63%), with three (11%) complete remissions. Moderate myelosuppression was the main toxic effect. Considering the advanced tumor staging (54% N3 tumors), this chemotherapeutic regimen appears as effective as other cisplatin-based chemotherapies.
Keywords
Adult Aged Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Carcinoma, Squamous Cell/*drug therapy Cisplatin/administration & dosage Drug Evaluation Female Head and Neck Neoplasms/*drug therapy Humans Male Middle Aged Mitomycins/administration & dosage Vindesine/administration & dosage
Pubmed
Web of science
Create date
28/01/2008 8:31
Last modification date
20/08/2019 16:21
Usage data